Sodium selenite and N-acetylcysteine in antiretroviralnaive HIV-1- infected patients: A randomized, controlled pilot study

European Journal of Clinical Investigation

Volumn 28, Issue 5, 1998, Pages 389-397

  Look, M P ^a   Rockstroh, J K ^a   Rao, G S ^a   Barton, S ^a   Lemoch, H ^a   Kaiser, R ^a   Kupfer, B ^a   Sudhop, T ^a   Spengler, U ^a   Sauerbruch, T ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Glutathione peroxidase; HIV infection; N acetylcysteine; Pilot study; Plasma glutathione; Selenium; Therapy trial

Indexed keywords

ACETYLCYSTEINE; SODIUM SELENITE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; LYMPHOCYTE SUBPOPULATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION REGULATION; VIRUS LOAD; VIRUS REPLICATION;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; ADULT; ERYTHROCYTES; FEMALE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; REFERENCE VALUES; SELENIUM; SODIUM SELENITE; T-LYMPHOCYTE SUBSETS; VIRAL LOAD;

EID: 7144264395     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00301.x     Document Type: Article

References (63)

1. Favier A, Sappey C, Leclerc P, Faure P, Micoud M. Antioxidant status and lipid peroxidation in patients infected with HIV. Chem Biol Interact 1994; 91: 165-80.
2. Greenspan HC. Role of reactive oxygen species, antioxidants and phytopharmaceuticals in human immunodeficiency virus activity. Med Hypotheses 1993; 40: 85-92.
3. Greensapan HC, Aruoma OI. Oxidative stress and apoptosis in HIV infection: a role for plant derived metabolites with synergistic antioxidant activity. Immunol Today 1994; 15: 209-13.
4. Halliwell B, Cross CE. Reactive oxygen species, antioxidants and acquired immunodeficiency syndrome. Sense or speculation? Arch Intern Med 1991; 151: 29-31.
5. Müller F. Reactive oxygen intermediates and human immunodefiency virus (HIV) infection. Free Rad Biol Med 1992; 13: 651-7.
6. Pace GW, Leaf CD. The role of oxidative stress in HIV disease. Free Rad Biol Med 1995; 19: 523-8.
7. Revillard JP, Vincent C, Favier AE, Richard MJ, Zittoun M, Kazatchkine MD. Lipid peroxidation in human immunodeficiency virus infection. J Aquir Immune Defic Syndr Hum Retrovir 1992; 5: 63-8.
8. Godfried MH, van der Poll T, Jansen J et al. Soluble receptors for tumor necrosis factor: A putative marker of disease progression in HIV infection. AIDS 1993; 7: 33-6.
9. + lymphocytes. Clin Exp Immunol 1993; 93: 350-5.
10. Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991; 5: 1405-17.
11. Roederer M, Ela SE, Staal FJT, Herzenberg LA, Herzenberg LA. N-Acertlcysteine: A new approach to anti-HIV therapy. AIDS Res Hum Retrovir 1992; 8: 209-17.
12. Staal FJT, Roederer M, Raju P et al. Antioxidants inhibit stimulation of HIV transcription. AIDS Res Hum Retrovir 1993; 9 (4): 299-06.
13. Roederer M, Staal FJT, Raju PA, Ela SW, Herzenberg LA, Herzenberg LA. Cytokine-stimulated HIV replication is inhibited by N-acetylcysteine. Proc Natl Acad Sci USA 1990; 87: 4884-8.
14. Ho WZ, Douglas SD. Glutathione and N-acetylcysteine suppression of human immunodeficiency virus replication in human monocyte/macrophages in vitro. AIDS Res Hum Retrovir 1992; 8: 1249-53.
15. Sappey C, Legrand-Poels S, Best-Belpomme M, Favier A, Rentier B, Piette J. Stimulation of glutathione peroxidase activity decreases HIV Type 1 activation after oxidative stress. AIDS Res Hum Retrovir 1994; 10: 1451-9.
16. Piette J, Legrand-Poels S. HIV-1 reactivation after an oxidative stress mediated by different reactive oxygen species. Chem Biol Interact 1994; 91: 79-89.
17. Roederer M, Staal FJT, Ela SW, Herzenberg IA, Herzenberg LA. N-Acetylcysteine: potential for AIDS therapy. Pharmacology 1993; 46: 121-9.
18. Kabelic T, Kinter A, Poli G, Anderson ME, Meister A, Fauci AS. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester and N-acetylcysteine. Proc Natl Acad Sci USA 1991; 88: 986-90.
19. Simon G, Moog C, Obert G. Effects of glutathione on human immunodeficiency virus replication. Chem Biol Interact 1994; 91: 217-24.
20. Nottet HSLM, van Asbeck S, de Graaf Loek de Vos NM, Visser MR, Verhoef J. Role for oxygen radicals in self-sustained HIV-1 replication by N-acetyl-1-cysteine. J Leuk Biol 1994; 56: 702-7.
21. Rotruck JT, Pope AL, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science 1973; 179: 588-90.
22. Dworkin BM. Selenium deficiency in HIV infection and the acquired immunodeficiency syndrome (AIDS). Chem Biol Interact 1994; 91: 181-6.
23. Look MP, Rockstroh JK, Rao GS et al. Serum selenium, plasma glutathione (GSH) and glutathione peroxidase (GSH-Px)-levels in asymptomytic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection. Eur J Clin Nutr 1997; 51: 266-72.
24. Dworkin BM, Rosenthal WS, Wormser GP et al. Abnormalities of blood selenium and glutathione peroxidase activity in patients with acquired immunodeficiency syndrome and aids-related complex. Biol Trace Elem Res 1988; 15: 167-77.
25. Buhl R, Holroyd KJ, Mastrangeli A et al. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet 1989; 2: 1294-7.
26. A (2): 798-801.
27. Cirelli A, Ciardi M, De Simone C et al. Serum selenium concentration and disease progress in patients with HIV infection. Clin Biochem 1991; 24: 211-4.
28. Passi S, Picardo M, Hamon C et al. Study on plasma polyunsaturated phospholipids and vitamin E and on erythrocyte glutathione peroxidase in high risk HIV infection categories and AIDS patients. Clin Chem Enzym Commun 1993; 5: 169-77.
29. Constans J, Pellegrin JL, Claire S et al. Serum selenium predicts outcome in HIV infection. J Aquir Immune Defic Syndr Hum Retrovir 1995; 10: 392.
30. Baum MK, Shor-Posner G, Lai S et al. High risk of HIV-related mortality is associated with selenium deficiency. AIDS Res Hum Retrovir 1997; 15: 370-4.
31. Eck HP, Gmünder H, Hartmann M, Petzoldt D, Daniel V, Dröge W. Low concentration of acid-soluble thiol (cysteine) in the blood plasma of HIV-1-infected patients. Biol Chem Hoppe Seyler 1989; 370: 101-8.
32. de Quay B, Malinverni R, Lauterburg BH. Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS 1992; 6: 815-9.
33. Barditch-Crovo P, Svobodov V, Lietman P. Apparent deficiency of glutathionine in the PBMCs of people with AIDS depends on method of expression. J Aquir Immune Defic Syndr Hum Retrovir 1995; 8: 313-4.
34. Flores SC, Marecki JC, Harper KP, Bose SK, Nelson SK, McCord JM. Tat protein of human immunodeficiency virus type 1 represses expression of manganese superoxide dismutase in HeLa cells. Proc Natl Acad Sci USA 1993; 90: 7632-6.
35. Westendorp MO, Shatrov VA, Schulze-Osthoff K et al. HIV-1 Tat potentiates TNF-induced NFκB activation and cytotoxicity by altering the cellular redox state. EMBO J 1995; 14: 546-54.
36. Ehret A, Westendorp MO, Herr I et al. Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis. J Virol 1996; 9: 6502-7.
37. Olmsted L, Schrauzer GN, Flores-Arce M, Dowd J. Selenium supplementation of symptomatic human immunodeficiency virus infected patients. Biol Trace Elem Res 1989; 20: 59-65.
38. Coodley GO, Nelson HD, Loveless MO, Folk C. β-carotene in HIV infection. J Aquir Immune Defic Syndr Hum Retrovir 1993; 6: 272-6.
39. Witschi A, Junker E, Schranz C, Speck RF, Lauterburg BH. Supplementation of N-acetylcysteine fails to increase glutathione in lymphocytes and plasma of patients with AIDS. AIDS Res Hum Retrovir 1995; 11 (1): 141-3.
40. Åkerlund B, Jarstrand C, Lindeke B, Sönnerborg A, Åkerblad AC, Rasool O. Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur J Clin Pharmacol 1996; 50: 457-61.
41. Kiremdjian-Schumacher L, Stotzky G. Selenium and immune responses (Review). Environ Res 1986; 42: 277-303.
42. Roy M, Kiremdjian-Schumacher L, Wishe HI, Cohnen MW, Stotzky G. Supplementation with selenium and human immune cell functions. Effect on lymphocyte proliferation and interleukin 2 receptor expression. Biol Trace Elem Res 1994; 41: 103-14.
43. Kiremidijan-Schumacher L, Roy M, Wishe HI, Cohen MW, Stotzky G. Supplementation with selenium and humane immune cell functions. Effect on cytotoxic lymphocytes and natural killer cells. Biol Trace Elem Res 1994; 41: 115-27.
44. Petrie HT, Klassen LW, Klassen PS, O'Dell JR, Kay HD. Selenium and the immune response: 2. Enhancement of murine cytotoxic T-lymphocyte and natural killer cell cytotoxicity in vivo. J Leukocyte Biol 1989; 45: 207-14.
45. Stabel JR, Spears JW. Nutrition and Immunology; Role of selenium in immune responsiveness and disease resistance. In: Klurfeld DM, ed. Human Nutrition - A Comprehensive Treatise. New York: Plenum Press, 1993: 333-56.
46. Perez A, Neve J, Duchatateau J, Siderova V, Famaey JP, Carpentier YA. Effects of selenium supplementation on immune parameters in gut failure patients on home parenteral nutrition. Nutrition 1991; 7 (3): 215-21.
47. Bonomini M, Forster S, De Risio F et al. Effects of selenium supplemetation on immune parameters in chronic uraemic patients. Nephrol Dial Transplant 1995; 10: 1654-61.
48. Makropoulos V, Bruning T, Schulze-Osthoff K. Selenium-mediated inhibition of transcription factor NF-kappa B and HIV-1 LTR promoter activity. Arch Toxicol 1996; 70: 277-83.
49. Mahalingam M, Pozniak A, McManus TJ, Vergani D, Peakman M. Cell cycling in HIV infection: analysis of in vivo activated lymphocytes. Clin Exp Immunol 1995; 102: 481-6.
50. Ferbas J, Kaplan AH, Hausner MA et al. Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determination of anti-HIV CD8+ lymphocyte activity. J Infect Dis 1995; 172 (2): 329-39.
51. Giorgi JV, Ho HN, Hirji K et al. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLD-DR+ CD38-CD8 cells is associated with subsequent stable CD4 cell levels. The Multicenter AIDS Cohort Study Group. J Infect Dis 1994; 170: 775-81.
52. Welz B, Melcher M, Schlemmer G. Bestimmung von Selen im menschlichen Blutserum. Anal Chem 1983; 316: 271-6.
53. Wendel A. Glutathione Peroxidase. Methods Enzymol 1981; 77: 325-33.
54. Tieze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione. Anal Biochem 1969; 27: 502-22.
55. Adams JT Jr, Bernhard H, Lauterberg BH, Mitchell JR. Plasma glutathione and glutathione disulfide in the rat: Regulation and response to oxidative stress. J Pharmacol Exp Ther 1983; 227: 749-54.
56. Helbling B, von Overbeck J, Lauterburg BH. Decreased release of glutathione into the systemic circulation of patients with HIV infection. Eur J Clin Invest 1996; 26: 38-44.
57. Burgunder JM, Varriale A, Burgunder BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989; 36: 127-31.
58. Cotgreave IA, Eklund A, Larsson K, Moldeus P. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur J Respir Dis 1987; 70: 73-7.
59. + lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection. Blood 1995; 86: 258-67.
60. Munir P, Williams D, Tingle MD et al. Intracellular glutathione in the peripheral blood cells of HIV-infected patients: failure to show a deficiency. AIDS 1996; 10: 501-7.
61. Herzenberg LA, De Rosa SC, Dubs JG et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci USA 1997; 94: 1967-72.
62. Beg AA, Baltimore D. An essential role for NF (B in preventing TNF-α-induced cell death. Science 1996; 274: 782-4.
63. Okamoto T, Sakurada S, Kato T et al. Redox regulation of the NFκB signaling pathway and disease control (Abstract).. Conference on Oxidative Stress and Redox Regulation: Cellular Signalling, AIDS, Cancer and Other Diseases. Paris, May 1996, p. 53.